Lantheus joins Bracco for promotion of CardioGen-82
Lantheus Medical Imaging has entered an agreement to co-promote Bracco’s CardioGen-82, a myocardial perfusion PET imaging agent.
CardioGen-82 (Rubidium Rb 82 generator) is an FDA-approved PET perfusion agent, which qualifies for reimbursements for the evaluation of coronary artery disease, according to the North Billerica, Mass.-based Lantheus and the Princeton, N.J.-based Bracco.
Don Kiepert, president and CEO of Lantheus, said the co-promotion agreement is a fit for the company and demonstrates its commitment to the field of diagnostic imaging through its distribution network, customer service and sales and medical affairs field organization.
CardioGen-82 (Rubidium Rb 82 generator) is an FDA-approved PET perfusion agent, which qualifies for reimbursements for the evaluation of coronary artery disease, according to the North Billerica, Mass.-based Lantheus and the Princeton, N.J.-based Bracco.
Don Kiepert, president and CEO of Lantheus, said the co-promotion agreement is a fit for the company and demonstrates its commitment to the field of diagnostic imaging through its distribution network, customer service and sales and medical affairs field organization.